NCT00944541

Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration

Pilot Study Evaluating Maraviroc (Celsentri®)Intensification Benefit in HIV Infected Patients Presenting Insufficient Immune Restoration Despite Controlled Viral Load With Antiretroviral Treatment. ANRS 145 MARIMUNO

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: French National Agency for Research on AIDS and Viral Hepatitis · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This pilot study aims to evaluate Maraviroc intensification strategy during 24 weeks in HIV infected patients under efficient (CV\< 50 cp/mL), controlled antiretroviral therapy (≥ 6 months) and uncompleted immune restoration (CD4\<350 cells/mL and CD4 earning \<100 cells/mL during last 24 months). The study will include 60 patients whose follow up is carried out for 48 weeks. recruitment period will be maintained for 12 months.

Conditions

• HIV Infection
• HIV Infections

Interventions

Type	Name	Description
DRUG	maraviroc	maraviroc 150 mg or 300 mg or 600 mg twice a day for 24 weeks

Timeline

• Start date: 2009-09-01
• Primary completion: 2010-08-01
• Completion: 2011-01-01
• First posted: 2009-07-23
• Last updated: 2026-04-06

Locations

1 site across 1 country: France